A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Have advanced breast cancer or another solid tumor with the presence of a phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) H1047R mutation (or other Sponsor and safety review committee (SRC)-approved, activating PIK3CA mutations other than H1047R mutation)Have adequate archival tumor tissue sample available or be approved by the Sponsor for enrollment if no tumor sample is available. Have stopped all cancer treatment and have recovered from the major side effects Have adequate organ function, as measured by blood tests Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale

Patients must have

Measurable disease

--- Patients with non-breast tumor types must have at least 1 measurable lesion

Non-measurable bone disease (at least 1 bone lesion in breast cancer patients only)

For patients with an estrogen receptor (ER)+ breast cancer diagnosis:

If female, must be postmenopausalIf male, must agree to use hormone suppression

Phase 1a:

-- Dose escalation and backfill patients:

Advanced solid tumorPatients may have had up to 5 prior regimens for advanced disease

Phase 1b:

Part A:

ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancerPatients may have had up to 5 prior regimens for advanced disease ---- Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required

Part B:

ER+/HER2- advanced breast cancerPatients may have had up to 2 prior regimens for advanced disease.

Part C:

ER+/HER2- advanced breast cancer

Patients may have had up to 5 prior regimens for advanced disease.

---- Prior CDK4/6 inhibitor therapy required.

Have a diagnosis of diabetes mellitus Type 2

Part D:

Advanced breast cancerPatients may have had up to 5 prior regimens for advanced disease.

Part E:

Advanced solid tumorPatients may have had up to 3 prior regimens for advanced disease advanced disease

Part F:

ER+/HER2- advanced breast cancer

Patients may have had up to 5 prior regimens for advanced disease

Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required